Loading...
Market
Will Merck's Clesrovimab receive FDA approval for RSV prevention in infants by the end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA announcements and Merck press releases
Story
Merck Announces Positive Phase 2b/3 Results for Clesrovimab in RSV Prevention Trial for Infants
Jul 23, 2024, 12:30 PM
Merck has announced positive topline results from its Phase 2b/3 trial of Clesrovimab (MK-1654), an investigational monoclonal antibody designed to prevent respiratory syncytial virus (RSV) in infants. The antibody-based drug met the main goal of reducing the incidence of lower respiratory infection compared to a placebo in a mid-to-late stage trial. The study, announced on Tuesday, also confirmed the safety profile of the treatment. Merck's announcement highlights the potential of Clesrovimab to protect infants from RSV-related diseases.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 50% • 25%
50% to 60% • 25%
60% to 70% • 25%
More than 70% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%